Gilead Sciences (NASDAQ:GILD) declined 3.84% yesterday. I believe that created a major buying opportunity as it's likely based on investors' (yet) limited understanding on Gilead’s strong positioning based on its anti-viral therapy Remdesivir in the battle against COVID-19.
The iShares Nasdaq Biotechnology ETF (IBB) was off by 2.5% and SPDR Biotech ETF (XBI) by 3% yesterday. But it still surprised me Gilead was off that much because there was good news in that Bruce Aylward, senior advisor and international leader of the World Health Organization's China COVID-19 mission,